Genprex Collaborators Report Positive Preclinical Data for Diabetes Gene Therapy at ASGCT 2026, Showing Alpha-to-Beta Cell Reprogramming

PR Newswire USA

Overview

Genprex’s collaborators presented positive preclinical data at ASGCT 2026 for GPX-002, a gene therapy candidate for Type 2 Diabetes (T2D). The therapy, which delivers Pdx1/MafA genes to the pancreas via an AAV vector, demonstrated improved hyperglycemia within four weeks in T2D mouse models by converting alpha cells into functional beta-like cells. Electron microscopy and transcriptome analyses confirmed an increase in mature insulin granules and a shift to a more mature beta cell phenotype, indicating a promising new approach to restore endogenous insulin production.

In Depth

Background

Type 2 Diabetes (T2D) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic beta-cell dysfunction, leading to insufficient insulin production. Current treatments primarily focus on glycemic control but do not address the fundamental loss of beta-cell mass or function. This significant unmet medical need has spurred the development of innovative therapeutic strategies, including gene therapy approaches aimed at restoring endogenous insulin production by reprogramming pancreatic cell fates.

Key Findings / Results

At the 2026 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, collaborators of Genprex presented encouraging preclinical findings for GPX-002, their gene therapy candidate for Type 2 Diabetes. The therapy involves the direct delivery of Pdx1 and MafA genes to the pancreas using an adeno-associated virus (AAV) vector. This genetic intervention successfully converted pancreatic alpha cells into functional beta-like cells capable of producing insulin. In T2D mouse models, GPX-002 demonstrated a notable improvement in hyperglycemia within just four weeks of treatment. Further mechanistic insights were provided through electron microscopy, which revealed an increase in mature insulin granules and a decrease in immature ones in treated pancreata. Transcriptome analysis corroborated these findings, indicating a phenotypic shift of the newly formed beta-like cells from an immature to a more mature and functional state.

Technical Significance & Outlook

The reported preclinical data for GPX-002 highlight a technically novel approach to T2D therapy by targeting the cellular plasticity of the pancreas. Converting existing alpha cells into insulin-producing beta-like cells directly addresses the core pathophysiology of T2D—beta-cell insufficiency—without requiring cell transplantation. This could offer a durable solution for glycemic control, potentially reducing or eliminating the need for exogenous insulin and current anti-diabetic medications. The precise AAV-mediated delivery of specific transcription factors represents a significant advance in gene therapy for metabolic diseases. While these results are currently at the preclinical stage, successful translation into human clinical trials could position GPX-002 as a paradigm-shifting therapy, offering a transformative alternative to millions of T2D patients worldwide by restoring the body’s natural ability to regulate blood glucose.